Ocena progresji POChP na podstawie badania spirometrycznego i zdolności wysiłkowej by Trzaska-Sobczak, Marzena et al.
www.pneumonologia.viamedica.pl
PRACA ORYGINALNA
288
Address for correspondence: Marzena Trzaska-Sobczak, MD, PhD, Department and Clinic of Pulmonology, Medical University of Silesia in Katowice, ul. Medyków 14, 
40–752 Katowice, Tel.: +48 32 252 38 31, e-mail: trzaska@mp.pl
Praca wpłynęła do Redakcji: 14.09.2012
Copyright © 2013 PTChP
ISSN 0867–7077
Marzena Trzaska-Sobczak1, Grzegorz Brożek2, Małgorzata Farnik1, Władysław Pierzchała1
1Department and Clinic of Pulmonology, Medical University of Silesia in Katowice
 Head: Prof. W. Pierzchała, MD, PhD
2Department and Unit of Epidemiology, Medical University of Silesia in Katowice
 Head: Prof. J.E Zejda, MD, PhD 
Evaluation of COPD progression based on spirometry and exercise 
capacity
Ocena progresji POChP na podstawie badania spirometrycznego i zdolności 
wysiłkowej
Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is characterized by an airflow limitation that is usually progres-
sive. The progression of COPD expressed as the rate of an annual decline in FEV1 is very heterogeneous. Exercise capacity 
in COPD patients is often diminished and becomes worsened over the time.
The purpose of the study was to examine how the change in FEV1 and exercise capacity would deteriorate over long-term 
observation. 
Material and methods: A total of 22 men with COPD were examined. At the beginning the average age was 59 ± 8.1 years 
and the mean post-bronchodilator FEV1 was 52 ± 14.9% predicted. Pulmonary function testing was performed at entry and 
then each year for 10 years, and exercise testing on a cycle ergometer was performed at entry and after 10 years.
Results: FEV1 and maximum oxygen uptake (VO2max), maximum mechanical work (Wmax), maximum minute ventilation (VEmax) and 
maximum tidal volume (VTmax) declined significantly over the observation time. The mean annual decline in FEV1 was 42 ± 37 mL, and 
the mean decline for VO2max was 30 ± 15 mL/min/yr and 0.44 ± 0.25 mL/min/kg/yr. Regression analysis revealed that the changes 
in FEV1 do not predict changes in VO2max. We observed a correlation between the annual change in VEmax and annual change in VO2max 
(r = 0.51 p < 0.05). The baseline FEV1 (expressed as a percentage of predicted and in absolute values) is the predictor of 
FEV1 annual decline (r = 0.74 and 0.82; p < 0.05).
Conclusions: We observed over time deterioration in exercise capacity in COPD patients which is independent of decline 
in airflow limitation. The long term follow-up of exercise capacity is important in monitoring of COPD patients in addition to 
pulmonary function.
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Streszczenie
Wstęp: Przewlekła obturacyjna choroba płuc (POChP) charakteryzuje się trwałym ograniczeniem przepływu powietrza przez 
dolne drogi oddechowe, które zwykle postępuje. Tempo progresji POChP wyrażane wielkością rocznego ubytku natężonej 
objętości wydechowej pierwszosekundowej (FEV1) jest bardzo zróżnicowane. Przewlekła obturacyjna choroba płuc powoduje 
zmniejszenie zdolności wysiłkowej, które zwykle pogłębia się w miarę upływu choroby. 
Celem pracy była ocena progresji POChP na podstawie wielkości rocznego ubytku FEV1 oraz zdolności wysiłkowej wyrażonej 
maksymalną konsumpcją tlenu (VO2max) w okresie 10 lat obserwacji.
Materiał i metody: Grupę badaną stanowiło 22 mężczyzn chorych na POChP w wieku 59,4 ± 8,1 roku, u których wyjścio-
wa wartość FEV1 po leku rozszerzającym oskrzela wynosiła 52 ± 14,9%. Badania czynnościowe układu oddechowego były 
przeprowadzane na początku oraz co roku przez 10 lat. Badania wysiłkowe wykonano na początku i po 10 latach. 
Wyniki: Wartość FEV1 oraz wskaźniki uzyskane podczas badania wysiłkowego — maksymalne zużycie tlenu (VO2max), mak-
symalna praca mechaniczna (Wmax), maksymalna wentylacja minutowa (VEmax) oraz maksymalna objętość oddechowa (VTmax) uległy 
istotnym zmianom po 10 latach: FEV1 obniżyło się średnio o 42 ± 37 ml na rok, a średni ubytek VO2max wynosił 30 ± 15 ml/min/rok 
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i 0,44 ± 0,25 ml/min/kg/rok. Nie stwierdzono korelacji między rocznym ubytkiem FEV1 i rocznym ubytkiem VO2max. Wykazano 
dodatnią korelację między rocznym ubytkiem VEmax i rocznym ubytkiem VO2max (r = 0,51 p < 0,05). Wyjściowe FEV1 (wyrażone 
jako % wartości należnej i w wartościach bezwzględnych) koreluje z rocznym ubytkiem FEV1 (r = 0,74 i 0,82; p < 0,05).
Wnioski: Progresja POChP określana wielkością utraty FEV1 w ciągu roku wykazuje bardzo zróżnicowane tempo. Wraz z cza-
sem trwania choroby dochodzi do obniżenia zdolności wysiłkowej wyrażanej VO2max i jest to niezależne od tempa utraty FEV1. 
Ocena progresji POChP może być zatem dokonywana nie tylko na podstawie badania czynnościowego układu oddechowego, 
ale także badań wysiłkowych. 
Słowa kluczowe: POChP, zdolność wysiłkowa, progresja POChP
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Introduction
Chronic obstructive pulmonary disease 
(COPD) is characterized by a permanent airflow 
limitation, which is usually progressive [1]. The 
progression of COPD expressed as the rate of an-
nual decline in FEV1 is very heterogeneous [2–4]. 
Factors that increase annual decline in FEV1 are: 
cigarette smoking, advanced emphysematous chan-
ges, bronchial hyperresponsiveness and frequent 
exacerbations [2, 4–8]. The progression of COPD 
causes deterioration of efficiency of pulmonary 
ventilation and reduces exercise tolerance [9–11]. 
Thus far only a few publications have evaluated 
changes in exercise capacity over time, based on 
the 6-minute walk test (6MWT) [10, 11] or exercise 
testing with measurement of maximum oxygen 
consumption VO2max [9].
Numerous research projects have reported 
relationship between spirometric indices at 
rest (FEV1, VC, IC), the area under the curve 
MEFV (Aex) and exercise capacity in COPD 
patients [12–23]. We still know little about the 
influence respiratory impairment on exercise 
capacity in this group of patients during long-
term observation.
The purpose of the study was to evaluate 
COPD progression based on the annual decline 
in FEV1 and its influence on actual exercise capa-
city expressed as maximum oxygen consumption 
(VO2max) during 10 years of observation. 
Material and methods
 The examined group consisted of 22 men with 
COPD, in accordance with criteria defined by the 
GOLD guidelines [24].
Criteria for including patients in the group 
were the following: cigarette smoking history of 
minimum 10 pack-years, spirometric criteria — 
FEV1 %FVC < 0.7, and FEV1 after salbutamol < 
80% of lower limit of normal. The patients were 
examined in a stable period of the disease, without 
exacerbations over the preceding 6 weeks. At the 
moment of inclusion into the group and during 
observation the patients were diagnosed with any 
coexistent diseases, especially neoplastic or car-
diovascular system diseases.
The research was conducted within standard 
diagnostics of COPD patients treated in the Pulmo-
nary Outpatient Clinic SP CSK. 
Pulmonary function tests were conducted 
at least 12h after discontinuation of inhalatory 
drug application, bronchodilator, and according 
to current guidelines for the performance of 
spirometry [25, 26]. Spirometry was performed 
before and 15 minutes after inhalation of 400 ug 
of salbutamol using MasterLab (Jaeger). Predicted 
values were defined with the help of a computer 
program based on the standards described by 
Quanjer [27].
Exercise tests were performed on a cycle 
ergometer the following day, according to the 
Wasserman protocol [28]. In accordance with the 
guidelines, at the beginning of the test there was 
a 3-minute resting registration preceding a 3-mi-
nute warm-up (pedalling without load), and then 
exercise (pedalling at a speed of 60 rotations per 
minute), with gradually increased load up to the 
appearance of symptoms preventing continuation 
of exercise or up to the moment of the appearance 
of objective signs ordering cessation of the exercise 
[29, 30].
Pulmonary function tests were conducted once 
a year for 10 years, and exercise tests were perfor-
med at the beginning of observation and then they 
were repeated after 10 years. During observation 
neither cardiovascular system nor neoplastic dise-
ases appeared in the examined patients.
Statistical analysis was conducted with the aid 
of Statistica 10 software. Data analysis included 
calculations of mean values, standard deviation 
(SD) and range. Assuming a significant correlation 
coefficient p < 0.05, the Wilcoxon signed-rank 
test, Mann-Whitney U-test and Spearman rank 
correlation test were applied.
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Results
At the start of the observation 22 men at the 
age of 59.4 ± 8.1 years participated in the research. 
There were 11 current and 11 former cigarette 
smokers at the age of 56.9 ± 7.7 years (46–69) and 
61.9 ± 8.2 years (49–72), respectively. For the who-
le group the mean baseline post-bronchodilator 
FEV1 was 52 ± 14.9% of predicted value.
Baseline FEV1 in the group of former smokers 
was 49.45 ± 12.0 % of predicted value (28–65), 
and in the group of current smokers it was 54.54 
± 17.5% of predicted value (35–79). There was no 
significant difference in age (p = 0.1) or FEV1 (p = 
0.7) between the groups. 
Baseline results for the whole groups are pre-
sented  Table 1.
Volume of FEV1, dyspnoea intensification ac-
cording to MRC and the rates obtained during 
exercise test — maximum oxygen consumption 
(VO2max), maximum mechanical work (Wmax), maximum 
minute ventilation (VEmax) and maximum tidal volume 
(VTmax) changed significantly after 10 years. Only 
BMI did not significantly change (Tab. 2). In the 
whole group, decline in FEV1 was 42 ± 37 mL/yr 
(36–123 mL/yr). In 19 patients (86%) decline in FEV1 
of 51 ± 31 mL/yr (range 7–123 mL), on average, 
was noted, and in 3 patients (14%) an increase of 
13 ± 6 mL/yr (range 8–21 mL/yr). In the group of former 
smokers decline in FEV1 was 33 ± 23 mL/yr, and in 
the group of current smokers it was 51.4 ± 39 mL/yr. 
Dependence between baseline FEV1 expressed both 
as an absolute value and as a percentage of predic-
ted value, and an annual decline in FEV1 was noted 
(correlation coefficient was 0.82 and 0.74 p < 0.05 
respectively) (Fig. 1, 2).
A mean decline in VO2max was 30 ± 15 mL/min/yr 
and 0.44 mL ± 0.25 mL/min/kg/yr.
In the group of current smokers VO2max decre-
ased by 30 ± 18 mL/yr and 0.47 ± 0.28 mL/min/kg/ 
/yr, whereas in the group of former smokers the dec-
line in VO2max was 28 mL ± 13 mL/min/yr and 0.41 
± 0.24 mL/min/kg/yr. There was no significant dif-
ference in the results between former and current 
smokers. Annual decline in VEmax was 0.87 ± 1.16 
L (1.8–3.2). The number of cigarettes smoked did 
Table 1. Baseline characteristics of the 22 men with COPD
Characteristics Mean Range
Age 59.4 ± 8.1 46–72
FEV1 [L] 1.55 ± 0.53 0.9–2.6
FEV1 (%w.n.) 52 ± 14.9 28–79
VO2max [mL/min/kg] 15.25 ± 5 8–27
VO2max [L/min] 1.18 ± 0.4 0.5–2
Wmax (W) 86.13 ± 31 30–150
VEmax [L] 43.18 ± 17.24 24–91
VTmax [L] 1.46 ± 0.41 0.7–2.4
BMI 24.8 ± 3.5 21–33
MRC 1.54 ± 0.8 0–3
Table 2. Final characteristics of the 22 men with COPD
Characteristics Mean Range P value
FEV1 [L] 1.13 ± 0.33 0.9–2.6  < 0.05
FEV1 (%w.n.) 41.5 ± 8.5 23–53  < 0.05
VO2max  
[mL/min/kg]
10.8 ± 4.44 5–25  < 0.0001
VO2max  
[mL/min]
0.89 ± 0.35 0.28–1.7  < 0.0001
Wmax 62 ± 25 20–130  < 0.0001
VEmax 43 ± 17.2 24–91  < 0.0001
VTmax 1.18 ± 0.36 0.63–2.2 0.0001
BMI 24.8 ± 4 20–34 NS
MRC 2 ± 0.7 1–3  < 0.0001
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Figure 2. Annual decline of FEV1 vs. baseline FEV1 (%pred.)
Figure 1. Annual decline of FEV1 vs. baseline FEV1 [L]
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not influence the annual decline in FEV1, VO2max 
or VEmax. Analysis of Spearman’s rank correlation 
showed dependence between the annual decline 
in VO2max and the annual decline in VEmax (r = 0.51 
p < 0.05) (Fig. 3). Correlations between the annual 
decline in FEV1 and the annual decline in VO2max or 
between the baseline FEV1 and the annual decline 
in VO2max were not noted.
Discussion
Numerous research projects that evaluated the 
annual decline in FEV1 in COPD have proven that 
it fluctuates between 25 and 69 mL/yr [2, 4–6, 9, 
31–34]. The annual decline concerning the exami-
ned patients was within these rates.
According to recent reports, COPD progres-
sion expressed as an annual decline in FEV1 is 
very heterogeneous [2, 3, 4]. The research project 
ECLIPSE showed that after 3 years of observation 
of 2,000 patients with COPD, an annual decline 
in FEV1 exceeded 40 mL/yr in 38% of patients. In 
31% of the rest of the patients a decline in FEV1 of 
between 21 and 40 mL was noted, and in 23% the 
change in FEV1 was between a decline of 20 mL/yr 
and an increase of 20 mL/yr. The increase in FEV1 
of 20 mL/yr was discovered in 8% of patients [2].
Nishimura et al., after 5 years of observation of 
279 patients with COPD, noted a group with more 
rapid annual decline in FEV1 (rapid decliners, 63 mL/ 
/yr), with a slow rate (slow decliners, 31 mL/yr), 
and patients who maintained pulmonary function 
on a constant level (sustainers, 2 mL/yr) [4]. During 
our observation, despite the small group of pa-
tients, we also noted a heterogeneous rate of annual 
decline in FEV1. During the 10-year observation 
a decline in FEV1 of 51 ± 31 mL/yr (range 7–123 
mL), on average, was noted in 19 patients (86%), 
and an increase of 13 ± 6 mL/yr (range 8–21 mL/yr) in 
3 patients (14%). Although the definition of COPD 
assumes the worsening of lung function, which 
may be expressed as a decline in FEV1, the present 
study and other reports [2, 3, 4] have proven that 
a significant decline in FEV1 does not always occur 
in the course of COPD. According to Nishimura et 
al., a faster rate of an annual decline in FEV1 occurs 
in patients with a greater intensification of emphy-
sema [4]. Researchers suggest that it may also be 
explained by the occurrence of various phenotypes 
of COPD [2, 4, 35]. Cessation of cigarette smoking 
may also result in the improvement of ventilation 
parameters, which has been proven in research 
conducted on large groups of patients [2, 4–7]. Due 
to the small number of patients in the examined 
group, it is difficult to draw conclusions about the 
cause for such variability of FEV1 and the cause for 
the increase in FEV1. Nevertheless, the patients 
with an observed improvement of lung function, 
despite constant airway obstruction, had stopped 
smoking at the beginning of observation, which 
may be the cause for the observed increase in FEV1.
Cigarette smoking is not only the main risk fac-
tor of COPD, but also it influences the progression 
rate expressed as a decline in FEV1 [2, 6, 7, 31–33].
Our group consisted of men, including former 
and current cigarette smokers. The difference in an 
annual decline in FEV1 between former and current 
cigarette smokers was not statistically significant, 
probably due to the small study groups.
In the mentioned ECLIPSE research the annual 
decline in FEV1 was, on average, 21 mL/yr greater 
among cigarette smokers than among non-smo-
kers, which is similar to the results of our study 
[2]. Furthermore, patients with positive broncho-
dilatatory test and patients with emphysema of 
the chest, seen in CT, had an annual decline in 
FEV1 greater by 17 mL/yr and 13 mL/yr, respec-
tively [2]. The Lung Health Study (LHS), after 
5 years of observation, noted an annual decline in 
FEV1 of 31 mL/yr in former cigarette smokers, and 
62 mL/yr in current smokers [7].
The same research, after 11 years of ob-
servation of patients who ceased smoking at the 
beginning of the research, noted an annual dec-
line in FEV1 of 30.2 mL/yr in men and 21.5 mL 
in women. Current smokers had a significantly 
greater decline in FEV1: 66 mL/yr in men and 
54 mL/yr in women [6]. It should be emphasi-
zed that in the LHS the average age of patients 
was 48 years and that their COPD was at a mild 
stage of progression (mean FEV1 78% of predicted 
value).
In the UPLIFT research project, which involved 
a group with moderate and advanced stages of the 
Figure 3. Annual decline of VEmax [L] vs. annual decline of VO2max 
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disease, the average decline in FEV1 during 4 years 
was 59ml/yr in smokers, and 33 mL/yr in non- 
-smokers [32].
We showed that the number of cigarettes 
smoked did not influence the annual decline in 
FEV1. Such dependence has not been discovered 
by Vestbo et al., either [2].
However, baseline airway obstruction influen-
ced the decline in FEV1. We discovered a depen-
dence between annual decline in FEV1 and baseline 
FEV1, expressed both as an absolute value and as 
the percentage of the predicted value. The more 
advanced the stage of COPD, and consequently the 
smaller the FEV1, the smaller was the annual dec-
line in FEV1. Similar dependence has been found 
in other research [2, 3, 10, 32, 34].
The ECLIPSE study noted the most serio-
us decline in FEV1 at GOLD 2 stage (35 mL/ 
/yr), and it was significantly more marked than at 
GOLD 3 stage (25 mL/yr) [2]. Casanova et al. also 
discovered a significantly greater decline in FEV1 
during the mild stage (112 mL/yr) than during 
the advanced stage (61 mL/yr) [3]. Another study 
conducted by the same author also noted a greater 
decline in FEV1 at a mild stage of COPD than at an 
advanced stage (40 mL/yr and 10 mL/yr, respecti-
vely) [10].
Deterioration of exercise tolerance is one of 
the key symptoms of COPD. 
The progression of the disease leads to 
a further impairment in exercise capacity, which 
was proved using the 6-minute walk test (6-MWT) 
[10, 11] or ergospirometric exercise test with asses-
ment of maximum oxygen consumption (VO2max) 
[9]. Our study proved a significant deterioration 
of exercise capacity expressed as a decrease in 
maximum oxygen consumption. A similar decline 
in VO2max was noted by Oga et al. (32ml/min/yr and 
0.5 mL/min/kg/yr) during a shorter, 5-year period 
of observation [9]. It seems that one limitation is 
the lack of a control group. According to univer-
sally applied norms for exercise tests, defined by 
Jones et al. [36] and according to the ATS/ACCP 
recommendations [30], the mean annual decline 
in VO2max is 21 mL/min/yr, whereas in our group it 
was 30 mL/min/yr on average. 
Since cigarette smoking influences the pro-
gression rate expressed as an annual decline in 
FEV1, it seems probable that the rate of exerci-
se capacity deterioration will also depend on 
smoking. Our observation showed that cigarette 
smoking and the number of the cigarettes smo-
ked do not influence the annual decline in VO-
2max. Due to the small number of subjects in the 
studied group and the lack of relevant reports, 
verification of these conclusions in a research 
project conducted on a larger number of patients 
is recommended.
We did not find any dependence between the 
annual decline in FEV1 and that of VO2max. The 
study carried out by Oga et al. showed a small 
correlation between decline in FEV1 and VO2max 
(r = 0.05 p = 0.013) [9]. Pino-Plata et al. did not 
note any dependence between exercise capacity as-
sessed in 6MWT and annual decline in FEV1, either 
[11]. Therefore, deterioration of exercise capacity 
assessed in a simple 6-minute walk test or exercise 
testing with determination of VO2max is practically 
independent of the annual decline in FEV1.
Moreover, we did not show that the degree of 
baseline obstruction influences the rate of deterio-
ration of exercise capacity. Such dependence was 
also not noted by Oga et al., who, additionally, 
extended the analysis by other indexes — TLC, RV, 
FRC and DLco [9]. Thus, deterioration of exercise 
capacity cannot be predicted based on statistical 
parameters of lung function.
A positive correlation between annual decline 
in VEmax and annual decline in VO2max, which has 
been shown in the present study, suggests that the 
decrease in maximum exercise ventilation caused 
by disorders of breathing mechanics or by respira-
tory muscles dysfunction, significantly influences 
deterioration of exercise capacity during long-term 
observation.
 Conclusions
COPD progression defined by decline in FEV1 
during one year has shown to be very heteroge-
neous. In the course of the disease, a decrease in 
exercise capacity expressed as VO2max independent 
of decline in FEV1 appears. Therefore, evaluation 
of the COPD progression may be performed based 
not only on pulmonary function testing (especially 
FEV1), but also on exercise testing with determi-
nation of maximum oxygen consumption (VO2max).
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